首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1869575

连续生产市场：产业趋势及全球预测（至 2035 年）－依药物分子、生物製程阶段、产品类型、企业规模、生产用途、公司规模及主要地区划分

Continuous Manufacturing Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Drug Molecule, Stage of Bioprocessing, Product Manufactured, Scale of Operation, Purpose of Manufacturing, Company Size, and Key Geographical Regions

出版日期: 2025年10月24日 | 出版商:

Roots Analysis | 英文 481 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

连续生产市场

预计今年连续生产市场规模将达到 26 亿美元，到 2040 年将达到 42 亿美元，预测期内复合年增长率高达 4.9%。

市场机会多元化，涵盖以下区隔领域：

药物分子

生物製药
小分子

生物製程阶段

上游生物工艺
下游工艺

生产的产品类型

活性药物成分
最终剂量形式

业务规模

非临床/临床
商业化生产

生产目标

内部生产
合约生产
两者兼有

公司规模

小型
中型
大型

主要地理区域

北美
欧洲
亚太地区

连续生产市场：成长与趋势

传统药厂面临的诸多挑战包括生产週期长、资源利用效率低、成本增加、供应链复杂。为了因应这些挑战，产业内外各方都在加大研发投入，力求将製药生产从间歇式生产转变为连续式生产。在这些方案中，连续式生产已成为生物製药和小分子药物大规模生产的首选方法。连续式生产透过连续的製程来生产所需产品，该流程在单一生产週期内持续添加原料和试剂。这种连续製程减少了停机时间，优化了设备利用率，从而提高了效率和生产力，降低了单位成本（约 40-50%），并加快了药物的商业化。

此外，采用连续式生产还具有诸多优势，包括提高生产力、改善营运效率和确保产品品质的稳定性。值得注意的是，利害关係人正致力于透过引入自动化和即时监控来改善这些流程，以最大限度地减少人为错误并降低製程变异性。此外，FDA 等监管机构也积极鼓励采用连续式生产，并提供相关指南以加快采用该技术开发的药物的审批流程。

传统製造流程中高昂的人工成本、大量的停机时间和批次间的差异性正在推动对连续製药生产的需求，这种生产方式能够确保产品品质的稳定性并提高成本效益。此外，先进的即时监控和自动化技术的应用正在推动製药公司从多阶段批量生产技术向快速高效的连续生产转型。

连续製造市场：关键洞察

本报告深入分析了连续製造市场的现状，并指出了该行业潜在的成长机会。报告的主要结论包括：

目前，连续生物製药生产商的市场格局高度分散，既有新进入者，也有老牌企业。这些公司大多位于美国。

2. 全球有超过 45 家公司提供采用连续製造技术的生物製剂合约生产服务。其中 80% 的公司生产活性药物成分。

3. 为因应日益增长的生物製剂需求，各公司正在加强其在连续製造技术方面的技术专长，以高效生产高品质产品。

4.约有 50 家製造商声称拥有小分子药物的连续生产技术。其中超过 80% 的公司是大型或超大型企业。

5. 超过 80% 的小分子药物製造商采用连续生产技术，专注于使用流动技术进行原料药合成，从而提高其生产製程的安全性、效率和成本效益。

6. 约 55% 的连续生产合作项目是在过去三年内达成的，其中大部分是生产合约。

7. 约 35% 的公司正在建设新的生产设施，其中约 50% 的公司专注于生物製药和小分子药物的临床和商业规模连续生产。

8. 已向与连续生产相关的研究授予了总计 2500 万美元的资助，其中约 30% 的资助期限最长为三年。

9. 自 2020 年以来，已授予约 80 项与连续生产相关的专利。此外，其中大多数专利的独占期还有 17 年。

10. 目前，全球生物製药连续生产设施的总产能估计约为 225,000 公升。其中约 40% 的产能位于欧洲公司的设施中。

11. 在欧洲，约50%的总装置容量集中在提供临床和商业规模生产的大型製造工厂。

12. 预计2035年，生物製药连续生产市场将以4.9%的复合年增长率成长。目前，上游生物加工占了大部分市场占有率，其次是下游生物加工。

13. 目前，小分子药物占连续生产市场总量的65%以上。预计到2035年，北美将占主导地位，市场占有率超过90%。

连续生产市场：主要区隔市场

连续生产市场分为生物製剂和小分子化合物两大类。今年，小分子化合物占了大部分市场占有率（超过 65%）。这主要是因为小分子化合物的化学性质使其生产过程相对简单，而生物製剂则需要从活细胞中提取，且提取过程更为复杂。值得强调的是，生物製剂领域在预测期内有望保持较高的复合年增长率，因为其具有诸多优势，例如靶向特异性高、药物相互作用少，这些优势使其在包括癌症和罕见疾病在内的多种疾病的治疗中得到广泛应用。

依连续生产製程划分，全球市场可分为上游生物製程及下游生物製程。根据我们的研究结果，上游生物製程今年占了主导地位（约 95%）。上游製程为下游製程奠定了基础，包括最终产品的纯化和製剂。因此，上游製程的效率和品质会显着影响最终产品的产量和品质。

依生产的产品，小分子连续生产市场可分为活性药物成分及製剂。今年，製剂占了最大的市场占有率（约 65%）。这主要归功于製剂最终用户商业化审批数量的增加。此外，活性药物成分市场在预测期内也展现出巨大的成长潜力。

就生产规模而言，连续生产市场可分为临床前/临床阶段及商业化生产阶段。尤其值得注意的是，生物製药和小分子化合物的商业化生产目前占了连续生产市场的大部分占有率（约 90%）。随着基于灌注的连续生物製程技术在工业界的日益普及，这些技术已成为生产在生产条件下不稳定的生物活性药物成分的首选方案。此外，将这些製程融入现有工作流程，可以定期将最终产品与可能发生降解的组分分开。

依生产目的，连续生产市场可分为内部生产、合约生产、两者兼具。值得注意的是，今年合约生产将占生物製剂和小分子药物市场70%以上的占有率。这主要归功于合约製造商能够提供更完善的客製化解决方案，使製造商能够专注于自身的核心竞争力，而无需投入资源建立内部生产设施。此外，内部生产市场预计在预测期内将保持较高的复合年增长率。

依公司规模划分，连续生产市场可分为小型、中型和大型公司。到2025年，大型公司将占连续生产市场的大部分占有率（超过70%）。这是因为大型生物製剂和小分子药物生产商拥有专门的资源和能力，使其能够比中小型企业更快地将市场趋势应用于生产流程。此外，中型企业也不断投资扩大产能并优化连续生产流程，预计将带来显着的成长率。

本部分将揭示北美、欧洲和亚太地区等各区域的市场分布。根据我们的研究结果，欧洲预计将占生物製药（约 40%）和小分子药物（超过 50%）连续生产市场的大部分占有率。这主要归功于研发人员的努力，推动了各生产设施快速采用连续生产技术。值得注意的是，亚太地区的小分子药物连续生产市场预计将以相对快速的速度成长。这是由于各行业参与者扩大采用灵活的生态系统，以促进连续生产技术的应用并支持高品质药物的研发。

连续生产市场的主要参与者

AbbVie Contract Manufacturing
Abzena
AGC Biologics
Boehringer Ingelheim
Corden Pharma
Glatt
Kaneka
Phlow
Wuxi Biologics

Conventional drug production by pharmaceutical manufacturers is associated with various challenges, including prolonged production timelines, inefficiencies in resource utilization, higher costs, and supply chain complexities. To circumvent the above-mentioned challenges, industry and non-industry players are increasingly investing in R&D initiatives for transforming pharmaceutical manufacturing from batch processes to continuous methods. Among these options, continuous manufacturing has become a highly favored method for large-scale production of biologics and small molecules. Continuous manufacturing helps in generating the desired product through an ongoing process by consistently adding raw materials and reagents during one production cycle. This ongoing process reduces downtime and optimizes equipment usage, resulting in increased efficiency and productivity, lowered unit costs by (~40-50%), and faster drug commercialization.

Additionally, the implementation of continuous manufacturing provides multiple benefits, including enhanced productivity, improved operational efficiency, and uniform product quality. Interestingly, stakeholders are enhancing these procedures by incorporating automation and real-time monitoring, with an aim to minimize human errors and reduce inconsistencies in the process. Furthermore, regulatory agencies, such as the FDA actively endorses continuous manufacturing by providing guidelines that accelerate the approval process for drugs developed through this technique.

High labor expenses, significant downtime, and variability between batches in traditional manufacturing have driven the demand for continuous pharmaceutical production to guarantee consistent product quality and enhanced cost-effectiveness. Moreover, the implementation advanced real-time monitoring and automation technologies has driven pharmaceutical firms to transition from multi-step batch production techniques to fast and efficient continuous manufacturing

CONTINUOUS MANUFACTURING MARKET: KEY INSIGHTS

The report delves into the current state of the continuous manufacturing market and identifies potential growth opportunities within industry. The key takeaways of the report are:

1. The current market landscape of continuous biologic manufacturers is highly fragmented, featuring the presence of both new entrants and established players; majority of these players are based in the US.

2. More than 45 players offer contract manufacturing services for biologics using continuous manufacturing across the globe; of these, 80% of the players manufacture active pharmaceutical ingredients.

3. Owing to the rising demand for biologics, companies are upgrading their technical expertise in continuous manufacturing techniques to efficiently manufacture high quality products.

4. Close to 50 manufacturers claim to have expertise in continuous manufacturing of small molecules; more than 80% of these players are large and very large firms.

5. Over 80% of the continuous small molecule manufacturers are focused on synthesizing APIs by utilizing flow technology to enhance the safety, efficiency, and cost effectiveness of the production process.

6. Around 55% of the total partnerships and collaborations in the continuous manufacturing domain were inked in past three years; of these, most of the deals were manufacturing agreements.

7. Close to 35% of players have established new facilities; of these, around 50% are focused on both clinical and commercial scale continuous manufacturing of biologics and small molecules.

8. Grants worth USD 25 million have been awarded for research related to continuous manufacturing; ~30% of these grants extend a support period of up to three years.

9. Around 80 patents have been granted related to continuous manufacturing since 2020; further, majority of the patents have 17 years left until they lose their exclusivity.

10. Presently, the global installed biologics continuous manufacturing is estimated to be around 225,000 liters; around 40% of this capacity is installed in the facilities of players based in Europe.

11. Across Europe, nearly 50% of the total capacity is housed in large manufacturers' facilities that offer both clinical and commercial scale manufacturing.

12. The continuous biologics manufacturing market is likely to grow at a CAGR of 4.9%, till 2035; presently, majority of the market share is occupied by upstream bioprocessing followed by downstream bioprocessing

13. In the current year, small molecules account for over 65% of the overall continuous manufacturing market; By 2035, North America is expected to capture the majority share, exceeding 90% of the market.

CONTINUOUS MANUFACTURING MARKET: KEY SEGMENTS

Small Molecule Segment Holds the Largest Share of the Continuous Manufacturing Market

The continuous manufacturing market is segmented across biologics and small molecules. In the current year, small molecules segment captures the majority of the market share (>65%). This can be attributed to the simple production process of small molecules due to its chemical nature, in comparison to biologics, that require more complex extraction procedures from living cells. It is important to highlight that the biologics segment is likely to grow at a higher CAGR during the forecast period, driven by several advantages, such as high target specificity and fewer drug interactions which facilitate their application in treating various disorders, including cancer and rare disorders.

Upstream Bioprocessing is the Most Used Stage of Continuous Manufacturing Market

The global market by stage of continuous manufacturing is segmented across upstream bioprocessing and downstream bioprocessing. Based on our findings, the upstream bioprocessing holds the major share (~95%) in the current year. Upstream processing lays the foundation for downstream processing, which involves purification and formulation of the final product. Thus, efficiency and quality of the upstream processes significantly influence the yield and quality of the final product.

Finished Dosage Forms Dominates the Largest Share of the Continuous Manufacturing Market

The small molecules continuous manufacturing market based on products manufactured is segmented across active pharmaceutical ingredients and finished dosage forms. Finished dosage forms hold the largest share (~65%) in the present year. This is a result of the increase in the approvals for the commercialization of finished doses to end-user. Further, active pharmaceutical ingredients segment shows higher growth potential, during the forecast period.

Commercial Scale Segment Holds the Largest Share of the Continuous Manufacturing Market

In terms of scale of operation, the continuous manufacturing market is segmented across preclinical / clinical and commercial operations. It is worth highlighting that the commercial scale of operation for biologics and small molecules captures majority of the continuous manufacturing market share (~90%), currently. Owing to the increased industrial adoption of perfusion based continuous bioprocessing technologies, these technologies are preferred option for manufacturing of biologic APIs that are unstable under production conditions. Moreover, incorporation of these processes in the current workflow enables regular separation of the final product from by-products that may cause degradation.

Contract Manufacturing Segment Dominates the Continuous Manufacturing Market

In terms of purpose of manufacturing, the continuous manufacturing market is segmented across in-house manufacturing, contract manufacturing and both. It is worth highlighting that the contract manufacturing segment dominates (>70%) the market for both biologics and small molecules in the current year. This is due to the enhanced capability of contract manufacturers in delivering customized solutions, enabling manufacturers to concentrate on their core strengths instead of allocating resources to establish their own manufacturing facilities for the production process Further, in-house manufacturing segment is likely to grow at a higher CAGR during the forecast period.

By Company Size, Large Players Holds the Largest Share of the Continuous Manufacturing Market

In terms of company size, the continuous manufacturing market is based on the company size, such small, mid-sized and large. Large company segments hold majority continuous manufacturing market size (with >70% share) in 2025. This is a result of dedicated resources and capabilities with the large biologics / small molecule manufacturers which allows for rapid implementation of market trends in their manufacturing workflow as compared to mid-sized or small manufacturers. Further, mid-sized companies are undertaking continuous investments to expand their capabilities and streamline continuous manufacturing operations. As a result, they are likely to grow at a notable growth rate.

Asia-Pacific to Propel in the Continuous Manufacturing Sector in the Coming Years

This segment highlights the distribution of market across various geographies, such as North America, Europe, and Asia-Pacific. As per our findings, Europe is likely to capture majority share in both biologics (~40%) and small molecules (>50%) continuous manufacturing market. This is a result of the efforts of researchers in R&D activities to expedite the implementation of continuous manufacturing technologies across their facilities. It is worth highlighting that the small molecule continuous manufacturing market will grow at a relatively faster pace in Asia-Pacific. This is due to increasing adoption of flexible ecosystem by various industry players to facilitate the implementation of continuous manufacturing technologies and support the development of high-quality pharmaceutical products.

Primary Research Overview

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes detailed transcripts of interviews conducted with the following individuals:

Founder and Chief Executive Officer, Small Organization, US
Co-Founder and Chief Business Officer, Mid-sized Organization, US
Chief Executive Officer, Large Organization, India
Vice President Process Chemistry and Technology, Very Large Organization, US
General Site Manager, Small Organization, US
Technical Project Manager, Continuous Manufacturing and Crystallization, Very Large Organization, UK

Example Players in the Continuous Manufacturing Market

AbbVie Contract Manufacturing
Abzena
AGC Biologics
Boehringer Ingelheim
Corden Pharma
Glatt
Kaneka
Phlow
Wuxi Biologics

CONTINUOUS MANUFACTURING MARKET: RESEARCH COVERAGE

The report on continuous manufacturing market features insights into various sections, including:

Market Sizing and Opportunity Analysis: An in-depth analysis of current market opportunity and the future growth potential of continuous manufacturing market, focusing on key market segments, including [A] type of drug molecule, [B] stage of bioprocessing, [C] type of product manufactured, and [D] geographical regions.
Market Landscape: A comprehensive evaluation of service providers engaged in the continuous manufacturing market based on several relevant parameters, such as [A] type of player, [B] scale of operation, [C] type of dosage form, and [D] type of product manufactured, [E] year of establishment, [F] company size, and [G] location of headquarters.
Company Competitiveness Analysis: An insightful technology competitiveness and benchmarking analysis, based on various relevant parameters, such as [A] company strength, and [B] portfolio strength.
Company Profiles: Comprehensive profiles of leading service providers, featuring information on [A] company overview, [B] financial information (if available), [C] continuous manufacturing service portfolio, [D] continuous manufacturing facilities, [E] recent developments, and [E] future outlook statements.
Partnerships and Collaborations: A detailed analysis of partnerships inked between stakeholders in the continuous manufacturing market, based on several relevant parameters, such as [A] year of partnership, [B] type of partnership, [C] type of partner, [D] type of drug molecule, [E] type of product, [F] scale of operation, and [G] geography.
Recent Expansions: An in-depth analysis of expansions reported in the continuous manufacturing market, based on several relevant parameters, [A] year of expansion, [B] type of expansion, [C] scale of operation, [D] type of drug molecule, [E] type of product, [F] amount invested, and [G] facility area.
Grant Analysis: A detailed analysis of the various grants reported in the continuous manufacturing domain with relevant information across parameters, such as [A] year of grants award, [B] amount awarded, [C] funding institute center, [D] support period, [E] type of grant application, [F] purpose of grant award, [G] activity code, and [H] study section involved.
Patent Analysis: A detailed analysis of the various patents filed / granted in the continuous manufacturing domain, based on various mbols, [E] type of applicant, and [F] patent benchmarking analysis. parameters, such as [A] patent publication year, [B] patent application year, [C] patent jurisdiction, [D] CPC Sy
Gaps Associated with Continuous Bioprocessing: A detailed overview of various technology gaps related to continuous downstream bioprocessing that are currently preventing its implementation, including gaps related to bioburden control, continuous multi-column chromatography, continuous viral inactivation process, continuous viral filtration process, continuous ultrafiltration / diafiltration, continuous buffer supply considerations and continuous monitoring of downstream process.
Initiatives of Companies with In-House Continuous Capabilities: An overview of various initiatives taken by the leading pharmaceutical companies (in terms of revenues), covering both partnered as well as in-house projects.
Case Study - Continuous Manufacturing Equipment for Biologics: A case study of the companies offering technologies / equipment that can potentially be used in continuous manufacturing of biologics, providing information on the [A] geographical location of potential stakeholders and [B] the type of technology / equipment provided.
Case Study - Roadmap for the Adoption of Continuous Manufacturing Processes: A case study on the roadmap for the adoption of continuous manufacturing technique, discussing different strategies that can be followed by the company in order to adopt this technology or transition from batch manufacturing to continuous manufacturing.
Case Study - Modular Facilities in Pharmaceutical / Biotechnology Industry: A brief description on the concept of modularization, types of modules used in modular buildings and an overview of the modular building construction process
Capacity Analysis: A detailed analysis on the global installed continuous upstream bioprocessing capacity and global installed continuous small molecule API manufacturing capacity of various small, mid-sized, large, and very large companies engaged in this domain based on parameters such as [A] company size, [B] scale of operation, [C] type of player and [D] key geographical regions.
Market Impact Analysis: A thorough analysis of various factors, such as [A] drivers, [B] restraints, [C] opportunities, and [D] existing challenges that are likely to impact market growth.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

SECTION I: REPORT OVERVIEW

1. PREFACE

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
- 2.2.1. Market Landscape and Market Trends
- 2.2.2. Market Forecast and Opportunity Analysis
- 2.2.3. Comparative Analysis
2.3. Database Building
- 2.3.1. Data Collection
- 2.3.2. Data Validation
- 2.3.3. Data Analysis
2.4. Project Methodology
- 2.4.1. Secondary Research
  - 2.4.1.1. Annual Reports
  - 2.4.1.2. Academic Research Papers
  - 2.4.1.3. Company Websites
  - 2.4.1.4. Investor Presentations
  - 2.4.1.5. Regulatory Filings
  - 2.4.1.6. White Papers
  - 2.4.1.7. Industry Publications
  - 2.4.1.8. Conferences and Seminars
  - 2.4.1.9. Government Portals
  - 2.4.1.10. Media and Press Releases
  - 2.4.1.11. Newsletters
  - 2.4.1.12. Industry Databases
  - 2.4.1.13. Roots Proprietary Databases
  - 2.4.1.14. Paid Databases and Sources
  - 2.4.1.15. Social Media Portals
  - 2.4.1.16. Other Secondary Sources
- 2.4.2. Primary Research
  - 2.4.2.1. Types of Primary Research
    - 2.4.2.1.1. Qualitative Research
    - 2.4.2.1.2. Quantitative Research
    - 2.4.2.1.3. Hybrid Approach
  - 2.4.2.2. Advantages of Primary Research
  - 2.4.2.3. Techniques for Primary Research
    - 2.4.2.3.1. Interviews
    - 2.4.2.3.2. Surveys
    - 2.4.2.3.3. Focus Groups
    - 2.4.2.3.4. Observational Research
    - 2.4.2.3.5. Social Media Interactions
  - 2.4.2.4. Key Opinion Leaders Considered in Primary Research
    - 2.4.2.4.1. Company Executives (CXOs)
    - 2.4.2.4.2. Board of Directors
    - 2.4.2.4.3. Company Presidents and Vice Presidents
    - 2.4.2.4.4. Research and Development Heads
    - 2.4.2.4.5. Technical Experts
    - 2.4.2.4.6. Subject Matter Experts
    - 2.4.2.4.7. Scientists
    - 2.4.2.4.8. Doctors and Other Healthcare Providers
  - 2.4.2.5. Ethics and Integrity
    - 2.4.2.5.1. Research Ethics
    - 2.4.2.5.2. Data Integrity
- 2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control

3. MARKET DYNAMICS

3.1. Chapter Overview
3.2. Forecast Methodology
- 3.2.1. Top-down Approach
- 3.2.2. Bottom-up Approach
- 3.2.3. Hybrid Approach
3.3. Market Assessment Framework
- 3.3.1. Total Addressable Market (TAM)
- 3.3.2. Serviceable Addressable Market (SAM)
- 3.3.3. Serviceable Obtainable Market (SOM)
- 3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
- 3.4.1. Qualitative Forecasting
- 3.4.2. Correlation
- 3.4.3. Regression
- 3.4.4. Extrapolation
- 3.4.5. Convergence
- 3.4.6. Sensitivity Analysis
- 3.4.7. Scenario Planning
- 3.4.8. Data Visualization
- 3.4.9. Time Series Analysis
- 3.4.10. Forecast Error Analysis
3.5. Key Considerations
- 3.5.1. Demographics
- 3.5.2. Government Regulations
- 3.5.3. Reimbursement Scenarios
- 3.5.4. Market Access
- 3.5.5. Supply Chain
- 3.5.6. Industry Consolidation
- 3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview
4.2. Market Dynamics
- 4.2.1. Time Period
  - 4.2.1.1. Historical Trends
  - 4.2.1.2. Current and Forecasted Estimates
- 4.2.2. Currency Coverage
  - 4.2.2.1. Major Currencies Affecting the Market
  - 4.2.2.2. Factors Affecting Currency Fluctuations
  - 4.2.2.3. Impact of Currency Fluctuations on the Industry
- 4.2.3. Foreign Currency Exchange Rate
  - 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
  - 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 4.2.4. Recession
  - 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
  - 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
- 4.2.5. Inflation
  - 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 4.2.5.2. Potential Impact of Inflation on the Market Evolution
- 4.2.6. Interest Rates
  - 4.2.6.1. Interest Rates and Their Impact on the Market
  - 4.2.6.2. Strategies for Managing Interest Rate Risk
- 4.2.7. Commodity Flow Analysis
  - 4.2.7.1. Type of Commodity
  - 4.2.7.2. Origins and Destinations
  - 4.2.7.3. Values and Weights
  - 4.2.7.4. Modes of Transportation
- 4.2.8. Global Trade Dynamics
  - 4.2.8.1. Import Scenario
  - 4.2.8.2. Export Scenario
  - 4.2.8.3. Trade Policies
  - 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
  - 4.2.8.5. Impact of Trade Barriers on the Market
- 4.2.9. War Impact Analysis
  - 4.2.9.1. Russian-Ukraine War
  - 4.2.9.2. Israel-Hamas War
- 4.2.10. COVID Impact / Related Factors
  - 4.2.10.1. Global Economic Impact
  - 4.2.10.2. Industry-specific Impact
  - 4.2.10.3. Government Response and Stimulus Measures
  - 4.2.10.4. Future Outlook and Adaptation Strategies
- 4.2.11. Other Indicators
  - 4.2.11.1. Fiscal Policy
  - 4.2.11.2. Consumer Spending
  - 4.2.11.3. Gross Domestic Product (GDP)
  - 4.2.11.4. Employment
  - 4.2.11.5. Taxes
  - 4.2.11.6. Stock Market Performance
  - 4.2.11.7. Cross-Border Dynamics
4.3. Conclusion

SECTION II: QUALITATIVE INSIGHTS

5. EXECUTIVE SUMMARY

6. INTRODUCTION

6.1. Chapter Overview
6.2. Historical Evolution of Continuous Manufacturing
6.3. Continuous Manufacturing in the Pharmaceutical Industry
- 6.3.1. Regulatory Landscape
- 6.3.2. Early Adopters of Continuous Manufacturing
- 6.3.3. Anticipated Shift to Continuous Manufacturing
- 6.3.4. Batch Manufacturing versus Continuous Manufacturing
- 6.3.5. Key Challenges Associated with Continuous Manufacturing
- 6.3.6. Future Perspectives

SECTION III: MARKET OVERVIEW

7. MARKET LANDSCAPE: BIOLOGICS CONTINUOUS MANUFACTURERS

7.1. Chapter Overview
7.2. Biologics Continuous Manufacturers: Overall Market Landscape
- 7.2.1. Analysis by Year of Establishment
- 7.2.2. Analysis by Company Size
- 7.2.3. Analysis by Location of Headquarters
- 7.2.4. Analysis by Type of Player
- 7.2.5. Analysis by Scale of Operation
- 7.2.6. Analysis by Type of Biologic Manufactured
- 7.2.7. Analysis by Type of Product Manufactured
- 7.2.8. Analysis by Location of Continuous Manufacturing Facilities
- 7.2.9. Analysis by Type of Continuous Manufacturing Facility
- 7.2.10. Analysis by Stage of Bioprocessing
- 7.2.11. Analysis by Stage of Upstream Bioprocessing
- 7.2.12. Analysis by Stage of Downstream Bioprocessing
- 7.2.13. Analysis by Quality Certificates Obtained
- 7.2.14. Analysis by Range of Installed Capacity

8. COMPANY COMPETITIVENESS ANALYSIS: CONTINUOUS BIOLOGIC MANUFACTURERS

8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. Company Competitiveness Analysis: Continuous Biologics Manufacturers
- 8.4.1. Biologics Continuous Manufacturers based in North America
- 8.4.2. Biologics Continuous Manufacturers based in Europe
- 8.4.3. Biologics Continuous Manufacturers based in Asia-Pacific

9. MARKET LANDSCAPE: SMALL MOLECULES CONTINUOUS MANUFACTURERS

9.1. Chapter Overview
9.2. Small Molecule Continuous Manufacturers: Overall Market Landscape
- 9.2.1. Analysis by Year of Establishment
- 9.2.2. Analysis by Company Size
- 9.2.3. Analysis by Location of Headquarters
- 9.2.4. Analysis by Type of Player
- 9.2.5. Analysis by Scale of Operation
- 9.2.6. Analysis by Type of Dosage Form
- 9.2.7. Analysis by Type of Product Manufactured
- 9.2.8. Analysis by Location of Continuous Manufacturing Facilities
- 9.2.9. Analysis by Type of Continuous Manufacturing Process
- 9.2.10. Analysis by Stage of API Manufacturing
- 9.2.11. Analysis by Stage of FDF Manufacturing
- 9.2.12. Analysis by Quality Certificates Obtained

10. COMPANY COMPETITIVENESS ANALYSIS: CONTINUOUS SMALL MOLECULE MANUFACTURERS

10.1. Chapter Overview
10.2. Assumptions and Key Parameters
10.3. Methodology
10.4. Company Competitiveness Analysis: Continuous Small Molecule Manufacturers
- 10.4.1. Small Molecules Continuous Manufacturers based in North America
- 10.4.2. Small Molecules Continuous Manufacturers based in Europe
- 10.4.3. Small Molecules Continuous Manufacturers based in Asia-Pacific

SECTION IV: COMPANY PROFILES

11. COMPANY PROFILES: CONTINUOUS MANUFACTURING SERVICE PROVIDERS BASED IN NORTH AMERICA

11.1. Chapter Overview
11.2. AbbVie Contract Manufacturing
- 11.2.1. Company Overview
- 11.2.2. Financial Information
- 11.2.3. Continuous Manufacturing Service Portfolio
- 11.2.4. Continuous Manufacturing Facilities
- 11.2.5. Recent Developments and Future Outlook
11.3. Abzena
- 11.3.1. Company Overview
- 11.3.2. Continuous Manufacturing Service Portfolio
- 11.3.3. Continuous Manufacturing Facilities
- 11.3.4. Recent Developments and Future Outlook
11.4. AGC Biologics
- 11.4.1. Company Overview
- 11.4.2. Financial Information
- 11.4.3. Continuous Manufacturing Service Portfolio
- 11.4.4. Continuous Manufacturing Facilities
- 11.4.5. Recent Developments and Future Outlook
11.5. Phlow
- 11.5.1. Company Overview
- 11.5.2. Continuous Manufacturing Service Portfolio
- 11.5.3. Continuous Manufacturing Facilities
- 11.5.4. Recent Developments and Future Outlook

12. COMPANY PROFILES: CONTINUOUS MANUFACTURING SERVICE PROVIDERS BASED IN EUROPE

12.1. Chapter Overview
12.2. Boehringer Ingelheim
- 12.2.1. Company Overview
- 12.2.2. Financial Information
- 12.2.3. Continuous Manufacturing Service Portfolio
- 12.2.4. Continuous Manufacturing Facilities
- 12.2.5. Recent Developments and Future Outlook
12.3. Corden Pharma
- 12.3.1. Company Overview
- 12.3.2. Continuous Manufacturing Service Portfolio
- 12.3.3. Continuous Manufacturing Facilities
- 12.3.4. Recent Developments and Future Outlook
12.4. Glatt
- 12.4.1. Company Overview
- 12.4.2. Continuous Manufacturing Service Portfolio
- 12.4.3. Continuous Manufacturing Facilities
- 12.4.4. Recent Developments and Future Outlook

13. COMPANY PROFILES: CONTINUOUS MANUFACTURING SERVICE PROVIDERS BASED IN ASIA-PACIFIC

13.1. Chapter Overview
13.2. Kaneka
- 13.2.1. Company Overview
- 13.2.2. Financial Information
- 13.2.3. Continuous Manufacturing Service Portfolio
- 13.2.4. Continuous Manufacturing Facilities
- 13.2.5. Recent Developments and Future Outlook
13.3. WuXi Biologics
- 13.3.1. Company Overview
- 13.3.2. Financial Information
- 13.3.3. Continuous Manufacturing Service Portfolio
- 13.3.4. Continuous Manufacturing Facilities
- 13.3.5. Recent Developments and Future Outlook

SECTION V: MARKET TRENDS

14. PARTNERSHIPS AND COLLABORATIONS

14.1. Chapter Overview
14.2. Partnership Models
14.3. Continuous Manufacturing: Partnerships and Collaborations
- 14.3.1. Analysis by Year of Partnership
- 14.3.2. Analysis by Type of Partnership
- 14.3.3. Analysis by Year and Type of Partnership
- 14.3.4. Analysis by Type of Partner
- 14.3.5. Analysis by Type of Drug Molecule
- 14.3.6. Analysis by Type of Product
- 14.3.7. Analysis by Scale of Operation
- 14.3.8. Most Active Players: Analysis by Number of Partnerships
- 14.3.9. Analysis by Geography
  - 14.3.9.1. Analysis by Country
  - 14.3.9.2. Analysis by Continent

15. RECENT EXPANSIONS

15.1. Chapter Overview
15.2. Continuous Manufacturing: Recent Expansions
- 15.2.1. Analysis by Year of Expansion
- 15.2.2. Analysis by Type of Expansion
- 15.2.3. Analysis by Year and Type of Expansion
- 15.2.4. Analysis by Scale of Operation
- 15.2.5. Analysis by Type of Expansion and Scale of Operation
- 15.2.6. Analysis by Type of Drug Molecule
- 15.2.7. Analysis by Type of Expansion and Type of Drug Molecule
- 15.2.8. Analysis by Type of Product
- 15.2.9. Analysis by Amount Invested
- 15.2.10. Analysis by Facility Area
- 15.2.11. Most Active Players: Analysis by Number of Recent Expansions
- 15.2.12. Analysis by Location of Expansion
  - 15.2.12.1. Analysis by Country
  - 15.2.12.2. Analysis by Continent
- 15.2.13. Analysis by Location of Expansion (Continent) and Type of Expansion

16. GRANT ANALYSIS

16.1. Chapter Overview
16.2. Scope and Methodology
16.3. Continuous Manufacturing: Grants Analysis
- 16.3.1. Analysis by Year of Grants Award
- 16.3.2. Analysis by Amount Awarded
- 16.3.3. Analysis by Funding Institute Center
- 16.3.4. Analysis by Support Period
- 16.3.5. Analysis by Type of Grant Application
- 16.3.6. Analysis by Purpose of Grant Award
- 16.3.7. Analysis by Activity Code
- 16.3.8. Analysis by Study Section Involved
- 16.3.9. Popular NIH Departments: Analysis by Number of Grants
- 16.3.10. Analysis by Type of Recipient Organization
- 16.3.11. Prominent Program Officers: Analysis by Number of Grants
- 16.3.12. Popular Recipient Organizations: Analysis by Number of Grants
- 16.3.13. Popular Recipient Organizations: Analysis by Grant Amount
- 16.3.14. Analysis by Region of Recipient Organization

17. PATENT ANALYSIS

17.1. Chapter Overview
17.2. Scope and Methodology
17.3. Continuous Manufacturing: Patent Analysis
- 17.3.1. Analysis by Patent Publication Year
- 17.3.2. Analysis by Type of Patent and Publication Year
- 17.3.3. Analysis by Patent Application Year
- 17.3.4. Analysis by Patent Jurisdiction
- 17.3.5. Analysis by CPC Symbols
- 17.3.6. Analysis by Type of Applicant
- 17.3.7. Leading Industry Players: Analysis by Number of Patents
- 17.3.8. Leading Non-Industry Players: Analysis by Number of Patents
17.4. Patent Benchmarking Analysis
- 17.4.1. Analysis by Patent Characteristics
17.5. Patent Valuation
17.6. Leading Patents by Number of Citations

18. GAPS ASSOCIATED WITH CONTINUOUS BIOPROCESSING

18.1. Chapter Overview
18.2. Technological Gaps in Continuous Bioprocessing
- 18.2.1. Gaps related to Bioburden Control
- 18.2.2. Gaps related to Continuous Multi Column Chromatography
  - 18.2.2.1. Continuous Chromatography Systems
  - 18.2.2.2. Continuous Protein A Chromatography
  - 18.2.2.3. Continuous Anion Exchange Chromatography
  - 18.2.2.4. Continuous Flow-Through Processing
  - 18.2.2.5. Continuous Chromatography Media
- 18.2.3. Gaps related to Continuous Viral Inactivation
  - 18.2.3.1. Continuous Viral Inactivation in a Tubular Reactor
  - 18.2.3.2. Continuous Viral Inactivation Through Column Chromatography
  - 18.2.3.3. Continuous Viral Inactivation using Alternating Hold-Bags
- 18.2.4. Gaps related to Continuous Viral Filtration
- 18.2.5. Gaps related to Continuous Ultrafiltration / Diafiltration
- 18.2.6. Gaps related to Continuous Buffer Supply
- 18.2.7. Gaps related to Continuous On-line Monitoring
18.3. Other Gaps Associated with Continuous Bioprocessing
- 18.3.1. Gaps Related to Single-Use Technologies
- 18.3.2. Gaps Related to Process Automation
- 18.3.3. Regulatory Requirements
18.4. Concluding Remarks

19. INITIATIVES OF COMPANIES WITH IN-HOUSE CONTINUOUS CAPABILITIES

19.1. Chapter Overview
19.2. Continuous Manufacturing Initiatives undertaken by Leading Companies
- 19.2.1. Amgen
  - 19.2.1.1. In-House Initiatives
- 19.2.2. Boehringer Ingelheim
  - 19.2.2.1. In-House Initiatives
- 19.2.3. Bristol-Myers Squibb
  - 19.2.3.1. In-House Initiatives
  - 19.2.3.2. Partnered Initiatives
- 19.2.4. GSK
  - 19.2.4.1. In-House Initiatives
  - 19.2.4.2. Partnered Initiatives
- 19.2.5. Merck KGaA
  - 19.2.5.1. In-House Initiatives
  - 19.2.5.2. Partnered Initiatives
- 19.2.6. Novartis
  - 19.2.6.1. In-House Initiatives
  - 19.2.6.2. Partnered Initiatives
- 19.2.7. Pfizer
  - 19.2.7.1. In-House Initiatives
  - 19.2.7.2. Partnered Initiatives
- 19.2.8. Sanofi
  - 19.2.8.1. In-House Initiatives
  - 19.2.8.2. Partnered Initiatives

20. CASE STUDY 1: CONTINUOUS MANUFACTURING EQUIPMENT FOR BIOLOGICS

20.1. Chapter Overview
20.2. Biologics Continuous Manufacturing Equipment: Overall Market Landscape
- 20.2.1. Analysis by Type of Equipment
- 20.2.2. Analysis by Type of Manufacturing Process
- 20.2.3. Analysis by Stage of Bioprocessing
- 20.2.4. Analysis by Scale of Operation
20.3. Biologics Continuous Manufacturing Equipment: Developer Landscape
- 20.3.1. Analysis by Year of Establishment
- 20.3.2. Analysis by Company Size
- 20.3.3. Analysis by Location of Headquarters
- 20.3.4. Most Active Players: Analysis by Number of Biologics Continuous Manufacturing Equipment Offered

21. CASE STUDY 2: ROADMAP FOR THE ADOPTION OF CONTINUOUS MANUFACTURING PROCESSES

21.1. Chapter Overview
21.2. Challenges Associated with the Adoption of Continuous Manufacturing Processes
21.3. Key Strategies for the Adoption of Continuous Manufacturing Processes
- 21.3.1. Phase I: Process Development and Implementation
- 21.3.2. Phase II: Equipment / Technology Development and Installation
- 21.3.3. Phase III: Facility / Plant Development and Establishment
- 21.3.4. Phase IV: Product Development and Manufacturing

22. CASE STUDY 3: MODULAR FACILITIES IN PHARMACEUTICAL / BIOTECHNOLOGY INDUSTRY

22.1. Chapter Overview
22.2. Historical Background
22.3. The Concept of Modularization
- 22.3.1. Types of Modular Constructs
- 22.3.2. Modular Construction Process
22.4. Modular Construction in the Pharmaceutical Industry
- 22.4.1. Advantages of Modular Construction in the Pharmaceutical Industry
22.5. Modular Facility Manufacturers
- 22.5.1. Analysis by Type of Industry Served
- 22.5.2. Analysis by Geographical Coverage
- 22.5.3. Analysis by Type of Modular Construction
22.6. Modular Pharmaceutical Cleanrooms
- 22.6.1. Cleanroom Classifications and Current Standards
- 22.6.2. Regulations and Standards Concerning Modular Cleanroom Construction
- 22.6.3. Advantages of Modular Cleanrooms
22.7. Modular Cleanroom Providers
- 22.7.1. Analysis by Year of Establishment
- 22.7.2. Analysis by Location of Headquarters
- 22.7.3. Analysis by Type of Modular Cleanroom Offered
22.8. Conclusion

23. CAPACITY ANALYSIS: CONTINUOUS BIOLOGIC MANUFACTURERS

23.1. Chapter Overview
23.2. Key Assumptions and Methodology
- 23.2.1. Analysis by Range of Installed Capacity
- 23.2.2. Analysis by Company Size
- 23.2.3. Analysis by Scale of Operation
- 23.2.4. Analysis by Type of Player
- 23.2.5. Analysis by Location of Biologics Continuous Manufacturing Facility
  - 23.2.5.1. Analysis of Biologics Continuous Manufacturing Capacity Installed in North America
  - 23.2.5.2. Analysis of Biologics Continuous Manufacturing Capacity Installed in Europe
  - 23.2.5.3. Analysis of Biologics Continuous Manufacturing Capacity Installed in Asia-Pacific
- 23.2.6. Concluding Remarks

24. CAPACITY ANALYSIS: CONTINUOUS SMALL MOLECULES MANUFACTURERS

24.1. Chapter Overview
24.2. Key Assumptions and Methodology
- 24.2.1. Analysis by Range of Installed Capacity
- 24.2.2. Analysis by Company Size
- 24.2.3. Analysis by Scale of Operation
- 24.2.4. Analysis by Type of Player
- 24.2.5. Analysis by Location of Small Molecules Continuous Manufacturing Facility
  - 24.2.5.1. Analysis of Small Molecules Continuous Manufacturing Capacity Installed in North America
  - 24.2.5.2. Analysis of Small Molecules Continuous Manufacturing Capacity Installed in Europe
  - 24.2.5.3. Analysis of Small Molecules Continuous Manufacturing Capacity Installed in Asia-Pacific
- 24.2.6. Concluding Remarks

SECTION VI: MARKET FORECAST AND OPPORTUNITY ANALYSIS

25. GLOBAL CONTINUOUS MANUFACTURING MARKET

25.1. Chapter Overview
25.2. Assumptions and Methodology
25.3. Global Continuous Manufacturing Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 25.3.1. Scenario Analysis
  - 25.3.1.1. Conservative Scenario
  - 25.3.1.2. Optimistic Scenario
25.4. Key Market Segmentations

26. CONTINUOUS MANUFACTURING MARKET, BY TYPE OF DRUG MOLECULE

26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Continuous Manufacturing Market: Distribution by Type of Drug Molecule
- 26.3.1. Continuous Manufacturing Market for Biologics, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 26.3.1.1. Biologics Continuous Manufacturing Market for Upstream Bioprocessing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 26.3.1.2. Biologics Continuous Manufacturing Market for Downstream Bioprocessing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 26.3.2. Continuous Manufacturing Market for Small Molecules, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 26.3.2.1. Small Molecules Continuous Manufacturing Market for Active Pharmaceutical Ingredients, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 26.3.2.2. Small Molecules Continuous Manufacturing Market for Finished Dosage Forms, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
26.4. Data Triangulation and Validation

27. CONTINUOUS MANUFACTURING MARKET, BY SCALE OF OPERATION

27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. Biologics Continuous Manufacturing Market: Distribution by Scale of Operation
- 27.3.1. Biologics Continuous Manufacturing Market for Preclinical / Clinical Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 27.3.2. Biologics Continuous Manufacturing Market for Commercial Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
27.4. Small Molecules Continuous Manufacturing Market: Distribution by Scale of Operation
- 27.4.1. Small Molecules Continuous Manufacturing Market for Preclinical / Clinical Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 27.4.2. Small Molecules Continuous Manufacturing Market for Commercial Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
27.5. Data Triangulation and Validation

28. CONTINUOUS MANUFACTURING MARKET, BY PURPOSE OF MANUFACTURING

28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Biologics Continuous Manufacturing Market: Distribution by Purpose of Manufacturing
- 28.3.1. Biologics Continuous Manufacturing Market for Contract Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 28.3.2. Biologics Continuous Manufacturing Market for In-house Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 28.3.3. Biologics Continuous Manufacturing Market for Both, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
28.4. Small Molecules Continuous Manufacturing Market: Distribution by Purpose of Manufacturing
- 28.4.1. Small Molecules Continuous Manufacturing Market for Contract Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 28.4.2. Small Molecules Continuous Manufacturing Market In-house Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 28.4.3. Small Molecules Continuous Manufacturing Market for Both, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
28.5. Data Triangulation and Validation

29. CONTINUOUS MANUFACTURING MARKET, BY COMPANY SIZE

29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. Biologics Continuous Manufacturing Market: Distribution by Company Size
- 29.3.1. Biologics Continuous Manufacturing Market for Small Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 29.3.2. Biologics Continuous Manufacturing Market for Mid-sized Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 29.3.3. Biologics Continuous Manufacturing Market for Large Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
29.4. Small Molecules Continuous Manufacturing Market: Distribution by Company Size
- 29.4.1. Small Molecules Continuous Manufacturing Market for Small Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 29.4.2. Small Molecules Continuous Manufacturing Market for Mid-sized Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 29.4.3. Small Molecules Continuous Manufacturing Market for Large Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
29.5. Data Triangulation and Validation

30. CONTINUOUS MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS

30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Biologics Continuous Manufacturing Market: Distribution by Key Geographical Regions
- 30.3.1. Biologics Continuous Manufacturing Market in North America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 30.3.1.1. Biologics Continuous Manufacturing Market in the US, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 30.3.1.2. Biologics Continuous Manufacturing Market in Puerto Rico, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 30.3.2. Biologics Continuous Manufacturing Market in Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 30.3.2.1. Biologics Continuous Manufacturing Market in Germany, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 30.3.2.2. Biologics Continuous Manufacturing Market in Switzerland, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 30.3.2.3. Biologics Continuous Manufacturing Market in Belgium, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 30.3.2.4. Biologics Continuous Manufacturing Market in Ireland, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 30.3.2.5. Biologics Continuous Manufacturing Market in France, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 30.3.2.6. Biologics Continuous Manufacturing Market in Rest of Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 30.3.3. Biologics Continuous Manufacturing Market in Asia-Pacific, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 30.3.3.1. Biologics Continuous Manufacturing Market in China, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 30.3.3.2. Biologics Continuous Manufacturing Market in South Korea, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 30.3.3.3. Biologics Continuous Manufacturing Market in Singapore, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 30.3.3.4. Biologics Continuous Manufacturing Market in Taiwan, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 30.3.3.5. Biologics Continuous Manufacturing Market in India, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 30.3.3.6. Biologics Continuous Manufacturing Market in Japan, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 30.3.3.7. Biologics Continuous Manufacturing Market in Australia, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.4. Small Molecules Continuous Manufacturing Market: Distribution by Key Geographical Regions, 2018, Current Year and 2040
- 30.4.1. Small Molecules Continuous Manufacturing Market in North America, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 30.4.1.1. Small Molecules Continuous Manufacturing Market in the US, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 30.4.1.2. Small Molecules Continuous Manufacturing Market in Mexico, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 30.4.2. Small Molecules Continuous Manufacturing Market in Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 30.4.2.1. Biologics Continuous Manufacturing Market in Germany, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 30.4.2.2. Small Molecules Continuous Manufacturing Market in the UK, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 30.4.2.3. Small Molecules Continuous Manufacturing Market in Italy, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 30.4.2.4. Small Molecules Continuous Manufacturing Market in Switzerland, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 30.4.2.5. Small Molecules Continuous Manufacturing Market in France, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 30.4.2.6. Small Molecules Continuous Manufacturing Market in Belgium, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 30.4.2.7. Small Molecules Continuous Manufacturing Market in Rest of Europe, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 30.4.3. Small Molecules Continuous Manufacturing Market in Asia-Pacific, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 30.4.3.1. Small Molecules Continuous Manufacturing Market in China, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 30.4.3.2. Small Molecules Continuous Manufacturing Market in Japan, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 30.4.3.3. Small Molecules Continuous Manufacturing Market in Singapore, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 30.4.3.4. Small Molecules Continuous Manufacturing Market in South Korea, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 30.4.3.5. Small Molecules Continuous Manufacturing Market in India, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
30.5. Data Triangulation and Validation

SECTION VII: MARKET OPPORTUNITY ANALYSIS WITHIN GEOGRAPHICAL REGIONS

31. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

31.1. Continuous Manufacturing Market in North America: Distribution by Type of Drug Molecule
- 31.1.1. Continuous Manufacturing Market in North America for Biologics, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 31.1.1.1. Biologics Continuous Manufacturing Market in North America for Upstream Bioprocessing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 31.1.1.2. Biologics Continuous Manufacturing Market in North America for Downstream Bioprocessing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 31.1.2. Continuous Manufacturing Market in North America for Small Molecules, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 31.1.2.1. Small Molecules Continuous Manufacturing Market in North America for Active Pharmaceutical Ingredients, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 31.1.2.2. Small Molecules Continuous Manufacturing Market in North America for Finished Dosage Forms, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
31.2. Continuous Manufacturing Market in North America: Distribution by Scale of Operation
- 31.2.1. Biologics Continuous Manufacturing Market in North America for Preclinical / Clinical Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 31.2.2. Biologics Continuous Manufacturing Market in North America for Commercial Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 31.2.3. Small Molecules Continuous Manufacturing Market in North America for Preclinical / Clinical Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 31.2.4. Small Molecules Continuous Manufacturing Market in North America for Commercial Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
31.3. Continuous Manufacturing Market in North America: Distribution by Purpose of Manufacturing
- 31.3.1. Biologics Continuous Manufacturing Market in North America for Contract Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 31.3.2. Biologics Continuous Manufacturing Market in North America for In-House Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 31.3.3. Biologics Continuous Manufacturing Market in North America for Both, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 31.3.4. Small Molecules Continuous Manufacturing Market in North America for Contract Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 31.3.5. Small Molecules Continuous Manufacturing Market in North America for In-House Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 31.3.6. Small Molecules Continuous Manufacturing Market in North America for Both, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
31.4. Continuous Manufacturing Market in North America: Distribution by Company Size
- 31.4.1. Biologics Continuous Manufacturing Market in North America for Small Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 31.4.2. Biologics Manufacturing Market in North America for Mid-sized Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 31.4.3. Biologics Manufacturing Market in North America for Large Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 31.4.4. Small Molecules Continuous Manufacturing Market in North America for Small Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 31.4.5. Small Molecules Manufacturing Market in North America for Mid-sized Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 31.4.6. Small Molecules Manufacturing Market in North America for Large Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

32. MARKET OPPORTUNITY ANALYSIS: EUROPE

32.1. Continuous Manufacturing Market in Europe: Distribution by Type of Drug Molecule
- 32.1.1. Continuous Manufacturing Market in Europe for Biologics, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 32.1.1.1. Biologics Continuous Manufacturing Market in Europe for Upstream Bioprocessing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 32.1.1.2. Biologics Continuous Manufacturing Market in Europe for Downstream Bioprocessing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
- 32.1.2. Continuous Manufacturing Market in Europe for Small Molecules, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)
  - 32.1.2.1. Small Molecules Continuous Manufacturing Market in Europe for Active Pharmaceutical Ingredients, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035)

简介目录图表

List of Tables

Table 6.1 Comparison of Batch and Continuous Manufacturing Techniques
Table 7.1 Biologics Continuous Manufacturers: Information on Year of Establishment, Employee Count, Company Size and Location of Headquarters
Table 7.2 Biologics Continuous Manufacturers: Information on Scale of Operation, Type of Player, Type of Biologic Manufactured and Type of Product Manufactured
Table 7.3 Biologics Continuous Manufacturers: Information on Number of Continuous Manufacturing Facilities, Location of the Continuous Manufacturing Facilities and Type of Facility
Table 7.4 Biologics Continuous Manufacturers: Information on Stage of Bioprocessing, Stage of Upstream Bioprocessing and Stage of Downstream Bioprocessing
Table 7.5 Biologics Continuous Manufacturers: Information on Type of Upstream Manufacturing Process, Type of Downstream Manufacturing Process, Type of Overall Manufacturing Process and Quality Certificates Obtained
Table 7.6 Biologics Continuous Manufacturers: Information on Location of Continuous Manufacturing Facility and Installed Capacity
Table 9.1 Small Molecules Continuous Manufacturers: Information on Year of Establishment, Employee Count, Company Size and Location of Headquarters
Table 9.2 Small Molecules Continuous Manufacturers: Information on Scale of Operation, Type of Player, Type of Dosage Form and Type of Product Manufactured
Table 9.3 Small Molecules Continuous Manufacturers: Information on Number of Continuous Manufacturing Facilities and Location of Continuous Manufacturing Facilities
Table 9.4 Small Molecules Continuous Manufacturers: Information on Stage of Continuous API Manufacturing and Stage of Continuous FDF Manufacturing
Table 9.5 Small Molecules Continuous Manufacturers: Information on Type of API Manufacturing Process, Type of FDF Manufacturing Process and Quality Certificates Obtained
Table 11.1 Continuous Manufacturing Market: List of Service Providers based in North America
Table 11.2 AbbVie Contract Manufacturing: Company Overview
Table 11.3 AbbVie Contract Manufacturing: Continuous Manufacturing Service Portfolio
Table 11.4 AbbVie Contract Manufacturing: Continuous Manufacturing Facilities
Table 11.5 Abzena: Company Overview
Table 11.6 Abzena: Continuous Manufacturing Service Portfolio
Table 11.7 Abzena: Continuous Manufacturing Facilities
Table 11.8 Abzena: Recent Developments and Future Outlook
Table 11.9 AGC Biologics: Company Overview
Table 11.10 AGC Biologics: Continuous Manufacturing Service Portfolio
Table 11.11 AGC Biologics: Continuous Manufacturing Facilities
Table 11.12 AGC Biologics: Recent Developments and Future Outlook
Table 11.13 Phlow: Company Overview
Table 11.14 Phlow: Continuous Manufacturing Service Portfolio
Table 11.15 Phlow: Continuous Manufacturing Facilities
Table 11.16 Phlow: Recent Developments and Future Outlook
Table 12.1 Continuous Manufacturing Market: List of Service Providers based in Europe
Table 12.2 Boehringer Ingelheim: Company Overview
Table 12.3 Boehringer Ingelheim: Continuous Manufacturing Service Portfolio
Table 12.4 Boehringer Ingelheim: Continuous Manufacturing Facilities
Table 12.5 Boehringer Ingelheim: Recent Developments and Future Outlook
Table 12.6 Corden Pharma: Company Overview
Table 12.7 Corden Pharma: Continuous Manufacturing Service Portfolio
Table 12.8 Corden Pharma: Continuous Manufacturing Facilities
Table 12.9 Corden Pharma: Recent Developments and Future Outlook
Table 12.10 Glatt: Company Overview
Table 12.11 Glatt: Continuous Manufacturing Service Portfolio
Table 12.12 Glatt: Continuous Manufacturing Facilities
Table 13.1 Continuous Manufacturing Market: List of Service Providers based in Asia-Pacific
Table 13.2 Kaneka: Company Overview
Table 13.3 Kaneka: Continuous Manufacturing Service Portfolio
Table 13.4 Kaneka: Continuous Manufacturing Facilities
Table 13.5 WuXi Biologics: Company Overview
Table 13.6 WuXi Biologics: Continuous Manufacturing Service Portfolio
Table 13.7 WuXi Biologics: Continuous Manufacturing Facilities
Table 13.8 WuXi Biologics: Recent Developments and Future Outlook
Table 14.1 Continuous Manufacturing Market: List of Partnerships and Collaborations, Since Pre-2020
Table 14.2 Partnerships and Collaborations: Information on Type of Agreement (Country-wise and Region-wise)
Table 15.1 Continuous Manufacturing Market: List of Recent Expansions, Since 2018
Table 17.1 Patent Analysis: Top CPC Sections
Table 17.2 Patent Analysis: Top CPC Symbols
Table 17.3 Patent Analysis: Top CPC Codes
Table 17.4 Patent Analysis: Summary of Benchmarking Analysis
Table 17.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 17.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 17.7 Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 18.1 Overall Gaps and Opportunities Associated with Continuous Manufacturing
Table 19.1 Amgen: In-House Initiatives
Table 19.2 Boehringer Ingelheim: In-House Initiatives
Table 19.3 Bristol-Myers Squibb: In-House Initiatives
Table 19.4 Bristol-Myers Squibb: Partnered Initiatives
Table 19.5 GSK: In-House Initiatives
Table 19.6 GSK: Partnered Initiatives
Table 19.7 Merck: In-House Initiatives
Table 19.8 Merck: Partnered Initiatives
Table 19.9 Novartis: In-House Initiatives
Table 19.10 Novartis: Partnered Initiatives
Table 19.11 Pfizer: In-House Initiatives
Table 19.12 Pfizer: Partnered Initiatives
Table 19.13 Sanofi: In-House Initiatives
Table 19.14 Sanofi: Partnered Initiatives
Table 20.1 Biologics Continuous Manufacturing Equipment: Information on Developer, Type of Equipment, Manufacturing Process, Stage of Bioprocessing and Scale of Operation
Table 20.2 Biologics Continuous Manufacturing Equipment: List of Developers
Table 22.1 Modular Facility Manufacturers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 22.2 Cleanroom Classification Standards
Table 22.3 ISO and FED STD 209E: Cleanroom Classification
Table 22.4 Modular Cleanroom Providers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 23.1 Biologics Continuous Manufacturers: Information on Total Installed Capacity (Sample Data Set)
Table 23.2 Capacity Analysis: Average Continuous Biologics Manufacturing Capacity by Company Size (Sample Dataset)
Table 23.3 Global Installed Continuous Bioprocessing Capacity by Company Size (in Liters)
Table 24.1 Small Molecules Continuous Manufacturers: Information on Total Installed Capacity (Sample Data Set)
Table 24.2 Capacity Analysis: Average Continuous Small Molecule Manufacturing Capacity by Company Size (Sample Dataset)
Table 24.3 Annual, Global Installed Continuous Small Molecule Manufacturing Capacity (Kg/Year) by Company Size
Table 36.1 Biologics Continuous Manufacturers: Distribution by Year of Establishment
Table 36.2 Biologics Continuous Manufacturers: Distribution by Company Size
Table 36.3 Biologics Continuous Manufacturers: Distribution by Location of Headquarters
Table 36.4 Biologics Continuous Manufacturers: Distribution by Type of Player
Table 36.5 Biologics Continuous Manufacturers: Distribution by Scale of Operation
Table 36.6 Biologics Continuous Manufacturers: Distribution by Type of Biologic Manufactured
Table 36.7 Biologics Continuous Manufacturers: Distribution by Type of Product Manufactured
Table 36.8 Biologics Continuous Manufacturers: Distribution by Location of Continuous Manufacturing Facilities
Table 36.9 Biologics Continuous Manufacturers: Distribution by Type of Continuous Manufacturing Facility
Table 36.10 Biologics Continuous Manufacturers: Distribution by Stage of Bioprocessing
Table 36.11 Biologics Continuous Manufacturers: Distribution by Stage of Upstream Bioprocessing
Table 36.12 Biologics Continuous Manufacturers: Distribution by Stage of Downstream Bioprocessing
Table 36.13 Biologics Continuous Manufacturers: Distribution by Quality Certificates Obtained
Table 36.14 Biologics Continuous Manufacturers: Distribution by Range of Installed Capacity (in Liters)
Table 36.15 Small Molecules Continuous Manufacturers: Distribution by Year of Establishment
Table 36.16 Small Molecules Continuous Manufacturers: Distribution by Company Size
Table 36.17 Small Molecules Continuous Manufacturers: Distribution by Location of Headquarters
Table 36.18 Small Molecules Continuous Manufacturers: Distribution by Type of Player
Table 36.19 Small Molecules Continuous Manufacturers: Distribution by Scale of Operation
Table 36.20 Small Molecules Continuous Manufacturers: Distribution by Type of Dosage Form
Table 36.21 Small Molecules Continuous Manufacturers: Distribution by Type of Product Manufactured
Table 36.22 Small Molecules Continuous Manufacturers: Distribution by Location of Continuous Manufacturing Facilities
Table 36.23 Small Molecules Continuous Manufacturers: Distribution by Type of Continuous Manufacturing Process
Table 36.24 Small Molecules Continuous Manufacturers: Distribution by Stage of Continuous API Manufacturing
Table 36.25 Small Molecules Continuous Manufacturers: Distribution by Stage of Continuous FDF Manufacturing
Table 36.26 Small Molecules Continuous Manufacturers: Distribution by Quality Certificates Obtained
Table 36.27 AbbVie: Annual Revenues, Consolidated Financial Details, Since FY 2021 (USD Billion)
Table 36.28 AGC Biologics: Annual Revenues, Consolidated Financial Details, Since FY 2021 (JPY Billion)
Table 36.29 Boehringer Ingelheim: Annual Revenues, Consolidated Financial Details, Since FY 2021 (EUR Billion)
Table 36.30 Kaneka: Annual Revenues, Consolidated Financial Details, Since FY 2021 (JPY Billion)
Table 36.31 WuXi Biologics: Annual Revenues, Consolidated Financial Details, Since FY 2021 (RMB Billion)
Table 36.32 Partnerships and Collaborations: Cumulative Year-wise Trend, Since Pre-2020
Table 36.33 Partnerships and Collaborations: Distribution by Type of Partnership
Table 36.34 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since Pre-2020
Table 36.35 Partnerships and Collaborations: Distribution by Type of Partner
Table 36.36 Partnerships and Collaborations: Distribution by Type of Drug Molecule
Table 36.37 Partnerships and Collaborations: Distribution by Type of Product
Table 36.38 Partnerships and Collaborations: Distribution by Scale of Operation
Table 36.39 Most Active Players: Distribution by Number of Partnerships
Table 36.40 Partnerships and Collaborations: Local and International Agreements
Table 36.41 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 36.42 Recent Expansions: Cumulative Year-wise Trend, Since 2018
Table 36.43 Recent Expansions: Distribution by Type of Expansion
Table 36.44 Recent Expansions: Distribution by Year and Type of Expansion, Since 2018
Table 36.45 Recent Expansions: Distribution by Scale of Operation
Table 36.46 Recent Expansions: Distribution by Type of Expansion and Scale of Operation
Table 36.47 Recent Expansions: Distribution by Type of Drug Molecule
Table 36.48 Recent Expansions: Distribution by Type of Drug Molecule Manufactured and Type of Expansion
Table 36.49 Recent Expansions: Distribution by Type of Product
Table 36.50 Recent Expansions: Distribution by Amount Invested (USD Million)
Table 36.51 Recent Expansions: Distribution by Facility Area (square feet)
Table 36.52 Most Active Players: Distribution by Number of Expansions
Table 36.53 Recent Expansions: Distribution by Location of Expansion (Country)
Table 36.54 Recent Expansions: Distribution by Location of Expansion (Continent)
Table 36.55 Recent Expansions: Distribution by Location of Expansion (Continent) and Type of Expansion
Table 36.56 Grants Analysis: Cumulative Distribution by Year of Grant, Since 2020
Table 36.57 Grants Analysis: Distribution by Cumulative Amount Awarded (USD Million), Since 2020
Table 36.58 Grants Analysis: Distribution by Funding Institute Center
Table 36.59 Grants Analysis: Distribution by Support Period
Table 36.60 Grants Analysis: Distribution by Type of Grant Application
Table 36.61 Grants Analysis: Distribution by Purpose of Grant Award
Table 36.62 Grants Analysis: Distribution by Activity Code
Table 36.63 Grants Analysis: Distribution by Study Section Involved
Table 36.64 Popular NIH Departments: Distribution by Number of Grants
Table 36.65 Grants Analysis: Distribution by Type of Recipient Organization
Table 36.66 Prominent Program Officers: Distribution by Number of Grants
Table 36.67 Popular Recipient Organizations: Distribution by Number of Grants
Table 36.68 Popular Recipient Organizations: Distribution by Grant Amount (USD Million)
Table 36.69 Grants Analysis: Distribution by Region of Recipient Organization
Table 36.70 Patent Analysis: Distribution by Type of Patent
Table 36.71 Patent Analysis: Cumulative Distribution by Patent Publication Year, Since 2020
Table 36.72 Patent Analysis: Distribution by Type of Patent and Publication Year, Since 2020
Table 36.73 Patent Analysis: Distribution by Patent Application Year, Since Pre-2019
Table 36.74 Patent Analysis: Patent Jurisdiction
Table 36.75 Leading Industry Players: Distribution by Number of Patents
Table 36.76 Leading Non-Industry Players: Distribution by Number of Patents
Table 36.77 Patent Analysis: Distribution by Patent Age
Table 36.78 Continuous Manufacturing: Patent Valuation
Table 36.79 Biologics Continuous Manufacturing Equipment: Distribution by Type of Equipment
Table 36.80 Biologics Continuous Manufacturing Equipment: Distribution by Type of Manufacturing Process
Table 36.81 Biologics Continuous Manufacturing Equipment: Distribution by Stage of Bioprocessing
Table 36.82 Biologics Continuous Manufacturing Equipment: Distribution by Scale of Operation
Table 36.83 Biologics Continuous Manufacturing Equipment Providers: Distribution by Year of Establishment
Table 36.84 Biologics Continuous Manufacturing Equipment Providers: Distribution by Company Size
Table 36.85 Biologics Continuous Manufacturing Equipment Providers: Distribution by Location of Headquarters
Table 36.86 Most Active Players: Distribution by Number of Biologics Continuous Manufacturing Equipment Offered
Table 36.87 Continuous Manufacturing: Phase wise Key Strategies for the Adoption of Continuous Manufacturing Processes
Table 36.88 Process Development and Implementation (Phase I): Distribution by Type of Strategy Adopted
Table 36.89 Equipment / Technology Development and Installation (Phase II): Distribution by the Type of Strategy Adopted
Table 36.90 Facility / Plant Development and Establishment (Phase III): Distribution by the Type of Strategy Adopted
Table 36.91 Product Development and Manufacturing (Phase IV): Distribution by the Type of Strategy Adopted
Table 36.92 Modular Construction: Applications
Table 36.93 Steps Involved in Modular Construction
Table 36.94 Construction Timeline of Modular and Conventional Buildings
Table 36.95 Modular Construction: Advantages
Table 36.96 Modular Facility Manufacturers: Distribution by Type of Industry Served
Table 36.97 Modular Facility Manufacturers: Distribution by Geographical Coverage
Table 36.98 Modular Facility Manufacturers: Distribution by Type of Modular Construction
Table 36.99 Modular Cleanroom Providers: Distribution by Year of Establishment
Table 36.100 Modular Cleanroom Providers: Distribution by Location of Headquarters
Table 36.101 Modular Cleanroom Providers: Distribution of Headquarters (Country)
Table 36.102 Modular Cleanroom Providers: Distribution by Type of Modular Cleanroom Offered
Table 36.103 Global Installed Continuous Bioprocessing Capacity: Distribution by Range of Installed Capacity (in Liters)
Table 36.104 Global Installed Continuous Bioprocessing Capacity (in Liters): Distribution by Company Size
Table 36.105 Global Installed Continuous Bioprocessing Capacity: Distribution by Scale of Operation
Table 36.106 Global Installed Continuous Bioprocessing Capacity: Distribution by Type of Player
Table 36.107 Global Installed Continuous Bioprocessing Capacity: Distribution by Location of Continuous Manufacturing Facility
Table 36.108 Continuous Bioprocessing Capacity Installed in North in North America
Table 36.109 Continuous Bioprocessing Capacity Installed in Europe
Table 36.110 Continuous Bioprocessing Capacity Installed in Asia-Pacific
Table 36.111 Global Installed Continuous Small Molecule Manufacturing Capacity (Kg/Year): Distribution by Range of Installed Capacity
Table 36.112 Global Installed Continuous Small Molecule Manufacturing Capacity (Kg/ Year): Distribution by Company Size
Table 36.113 Global Installed Continuous Small Molecule Manufacturing Capacity (Kg/ Year): Distribution by Scale of Operation
Table 36.114 Global Continuous Small Molecule Manufacturing Capacity: Distribution by Type of Player
Table 36.115 Global Installed Continuous Small Molecule Manufacturing Capacity: Distribution by Location of Continuous Manufacturing Facility
Table 36.116 Continuous Small Molecule Manufacturing Capacity Installed in North America
Table 36.117 Continuous Small Molecule Manufacturing Capacity Installed in Europe
Table 36.118 Continuous Small Molecule Manufacturing Capacity Installed in Asia-Pacific
Table 36.119 Global Continuous Manufacturing Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Table 36.120 Global Continuous Manufacturing Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Million)
Table 36.121 Global Continuous Manufacturing Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Million)
Table 36.122 Continuous Manufacturing Market: Distribution by Type of Drug Molecule, 2021, 2025 and 2035
Table 36.123 Continuous Manufacturing Market for Biologics, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.124 Biologics Continuous Manufacturing Market for Upstream Bioprocessing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.125 Biologics Continuous Manufacturing Market for Downstream Bioprocessing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.126 Continuous Manufacturing for Small Molecules Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.127 Small Molecules Continuous Manufacturing Market for Active Pharmaceutical Ingredients, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.128 Small Molecules Continuous Manufacturing Market for Finished Drug Forms, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.129 Biologics Continuous Manufacturing Market: Distribution by Scale of Operation, 2021, 2025 and 2035
Table 36.130 Biologics Continuous Manufacturing Market for Preclinical / Clinical Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.131 Biologics Continuous Manufacturing Market for Commercial Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.132 Small Molecules Continuous Manufacturing Market: Distribution by Scale of Operation, 2021, 2025 and 2035
Table 36.133 Small Molecules Continuous Manufacturing Market for Preclinical / Clinical Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.134 Small Molecules Continuous Manufacturing Market for Commercial Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.135 Biologics Continuous Manufacturing Market: Distribution by Purpose of Manufacturing, 2021, 2025 and 2035
Table 36.136 Biologics Continuous Manufacturing Market for Contract Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.137 Biologics Continuous Manufacturing Market for In-House Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.138 Biologics Continuous Manufacturing Market for Both, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.139 Small Molecules Continuous Manufacturing Market: Distribution by Purpose of Manufacturing, 2021, 2025 and 2035
Table 36.140 Small Molecules Continuous Manufacturing Market for Contract Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.141 Small Molecules Continuous Manufacturing Market for In-House Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.142 Small Molecules Continuous Manufacturing Market for Both, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.143 Biologics Continuous Manufacturing Market: Distribution by Company Size, 2021, 2025 and 2035
Table 36.144 Biologics Continuous Manufacturing Market for Small Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.145 Biologics Continuous Manufacturing Market for Mid-Sized Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.146 Biologics Continuous Manufacturing Market for Large Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.147 Small Molecules Continuous Manufacturing Market: Distribution by Company Size, 2021, 2025 and 2035
Table 36.148 Small Molecules Continuous Manufacturing Market for Small Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.149 Small Molecules Continuous Manufacturing Market for Mid-Sized Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.150 Small Molecules Continuous Manufacturing Market for Large Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.151 Biologics Continuous Manufacturing Market: Distribution by Key Geographical Regions, 2021, 2025 and 2035
Table 36.152 Biologics Continuous Manufacturing Market in North America: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.153 Biologics Continuous Manufacturing Market in the US: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.154 Biologics Continuous Manufacturing Market in Puerto Rico: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.155 Biologics Continuous Manufacturing Market in Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.156 Biologics Continuous Manufacturing Market in Germany: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.157 Biologics Continuous Manufacturing Market in Switzerland: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.158 Biologics Continuous Manufacturing Market in Belgium: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.159 Biologics Continuous Manufacturing Market in Ireland: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.160 Biologics Continuous Manufacturing Market in France: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.161 Biologics Continuous Manufacturing Market in Rest of Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.162 Biologics Continuous Manufacturing Market in Asia-Pacific: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.163 Biologics Continuous Manufacturing Market in China: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.164 Biologics Continuous Manufacturing Market in South Korea: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.165 Biologics Continuous Manufacturing Market in Singapore: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.166 Biologics Continuous Manufacturing Market in Taiwan: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.167 Biologics Continuous Manufacturing Market in India: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.168 Biologics Continuous Manufacturing Market in Japan: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.169 Biologics Continuous Manufacturing Market in Australia: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.170 Biologics Continuous Manufacturing Market: Market Movement Analysis
Table 36.171 Biologics Continuous Manufacturing Market: Penetration Growth (P-G) Matrix
Table 36.172 Small Molecules Continuous Manufacturing Market: Distribution by Key Geographical Regions, 2021, 2025 and 2035
Table 36.173 Small Molecules Continuous Manufacturing Market in North America: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.174 Small Molecules Continuous Manufacturing Market in the US: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.175 Small Molecules Continuous Manufacturing Market in Mexico: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.176 Small Molecules Continuous Manufacturing Market in Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.177 Small Molecules Continuous Manufacturing Market in Germany: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.178 Small Molecules Continuous Manufacturing Market in the UK: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.179 Small Molecules Continuous Manufacturing Market in Italy: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.180 Small Molecules Continuous Manufacturing Market in Switzerland: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.181 Small Molecules Continuous Manufacturing Market in France: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.182 Small Molecules Continuous Manufacturing Market in Belgium: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.183 Small Molecules Continuous Manufacturing Market in Rest of Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.184 Small Molecules Continuous Manufacturing Market in Asia-Pacific: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.185 Small Molecules Continuous Manufacturing Market in China: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.186 Small Molecules Continuous Manufacturing Market in Singapore: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.187 Small Molecules Continuous Manufacturing Market in Japan: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.188 Small Molecules Continuous Manufacturing Market in India: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)
Table 36.189 Small Molecules Continuous Manufacturing Market in South Korea: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million): Conservative, Base and Optimistic Scenarios (USD Billion)

List of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Recent Trends
Figure 5.5 Executive Summary: Market Sizing and Opportunity Analysis
Figure 6.1 Advantages of Continuous Manufacturing
Figure 7.1 Biologics Continuous Manufacturers: Distribution by Year of Establishment
Figure 7.2 Biologics Continuous Manufacturers: Distribution by Company Size
Figure 7.3 Biologics Continuous Manufacturers: Distribution by Location of Headquarters
Figure 7.4 Biologics Continuous Manufacturers: Distribution by Type of Player
Figure 7.5 Biologics Continuous Manufacturers: Distribution by Scale of Operation
Figure 7.6 Biologics Continuous Manufacturers: Distribution by Type of Biologic Manufactured
Figure 7.7 Biologics Continuous Manufacturers: Distribution by Type of Product Manufactured
Figure 7.8 Biologics Continuous Manufacturers: Distribution by Location of Continuous Manufacturing Facilities
Figure 7.9 Biologics Continuous Manufacturers: Distribution by Type of Continuous Manufacturing Facility
Figure 7.10 Biologics Continuous Manufacturers: Distribution by Stage of Bioprocessing
Figure 7.11 Biologics Continuous Manufacturers: Distribution by Stage of Upstream Bioprocessing
Figure 7.12 Biologics Continuous Manufacturers: Distribution by Stage of Downstream Bioprocessing
Figure 7.13 Biologics Continuous Manufacturers: Distribution by Quality Certificates Obtained
Figure 7.14 Biologics Continuous Manufacturers: Distribution by Range of Installed Capacity (in Liters)
Figure 8.1 Company Competitiveness Analysis: Biologics Continuous Manufacturers based in North America
Figure 8.2 Company Competitiveness Analysis: Biologics Continuous Manufacturers based in Europe
Figure 8.3 Company Competitiveness Analysis: Biologics Continuous Manufacturers based in Asia-Pacific
Figure 9.1 Small Molecules Continuous Manufacturers: Distribution by Year of Establishment
Figure 9.2 Small Molecules Continuous Manufacturers: Distribution by Company Size
Figure 9.3 Small Molecules Continuous Manufacturers: Distribution by Location of Headquarters
Figure 9.4 Small Molecules Continuous Manufacturers: Distribution by Type of Player
Figure 9.5 Small Molecules Continuous Manufacturers: Distribution by Scale of Operation
Figure 9.6 Small Molecules Continuous Manufacturers: Distribution by Type of Dosage Form
Figure 9.7 Small Molecules Continuous Manufacturers: Distribution by Type of Product Manufactured
Figure 9.8 Small Molecules Continuous Manufacturers: Distribution by Location of Continuous Manufacturing Facilities
Figure 9.9 Small Molecules Continuous Manufacturers: Distribution by Type of Continuous Manufacturing Process
Figure 9.10 Small Molecules Continuous Manufacturers: Distribution by Stage of Continuous API Manufacturing
Figure 9.11 Small Molecules Continuous Manufacturers: Distribution by Stage of Continuous FDF Manufacturing
Figure 9.12 Small Molecules Continuous Manufacturers: Distribution by Quality Certificates Obtained
Figure 10.1 Company Competitiveness Analysis: Small Molecules Continuous Manufacturers based in North America
Figure 10.2 Company Competitiveness Analysis: Small Molecules Continuous Manufacturers based in Europe
Figure 10.3 Company Competitiveness Analysis: Small Molecules Continuous Manufacturer based in Asia-Pacific
Figure 11.1 AbbVie: Annual Revenues, Consolidated Financial Details, Since FY 2021 (USD Billion)
Figure 11.2 AGC Biologics: Annual Revenues, Consolidated Financial Details, Since FY 2021 (JPY Billion)
Figure 12.1 Boehringer Ingelheim: Annual Revenues, Consolidated Financial Details, Since FY 2021 (EUR Billion)
Figure 13.1 Kaneka: Annual Revenues, Consolidated Financial Details, Since FY 2021 (JPY Billion)
Figure 13.2 WuXi Biologics: Annual Revenues, Consolidated Financial Details, Since FY 2021 (RMB Billion)
Figure 14.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since Pre-2020
Figure 14.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 14.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, Since Pre-2020
Figure 14.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 14.5 Partnerships and Collaborations: Distribution by Type of Drug Molecule
Figure 14.6 Partnerships and Collaborations: Distribution by Type of Product
Figure 14.7 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 14.8 Most Active Players: Distribution by Number of Partnerships
Figure 14.9 Partnerships and Collaborations: Local and International Agreements
Figure 14.10Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 15.1 Recent Expansions: Cumulative Year-wise Trend, Since 2018
Figure 15.2 Recent Expansions: Distribution by Type of Expansion
Figure 15.3 Recent Expansions: Distribution by Year and Type of Expansion, Since 2018
Figure 15.4 Recent Expansions: Distribution by Scale of Operation
Figure 15.5 Recent Expansions: Distribution by Type of Expansion and Scale of Operation
Figure 15.6 Recent Expansions: Distribution by Type of Drug Molecule
Figure 15.7 Recent Expansions: Distribution by Type of Drug Molecule Manufactured and Type of Expansion
Figure 15.8 Recent Expansions: Distribution by Type of Product
Figure 15.9 Recent Expansions: Distribution by Amount Invested (USD Million)
Figure 15.10 Recent Expansions: Distribution by Facility Area (square feet)
Figure 15.11 Most Active Players: Distribution by Number of Expansions
Figure 15.12 Recent Expansions: Distribution by Location of Expansion (Country)
Figure 15.13 Recent Expansions: Distribution by Location of Expansion (Continent)
Figure 15.14 Recent Expansions: Distribution by Location of Expansion (Continent) and Type of Expansion
Figure 16.1 Grants Analysis: Cumulative Distribution by Year of Grant, Since 2020
Figure 16.2 Grants Analysis: Distribution by Cumulative Amount Awarded (USD Million), Since 2020
Figure 16.3 Grants Analysis: Distribution by Funding Institute Center
Figure 16.4 Grants Analysis: Distribution by Support Period
Figure 16.5 Grants Analysis: Distribution by Type of Grant Application
Figure 16.6 Grants Analysis: Distribution by Purpose of Grant Award
Figure 16.7 Grants Analysis: Distribution by Activity Code
Figure 16.8 Grants Analysis: Distribution by Study Section Involved
Figure 16.9 Popular NIH Departments: Distribution by Number of Grants
Figure 16.10 Grants Analysis: Distribution by Type of Recipient Organization
Figure 16.11 Prominent Program Officers: Distribution by Number of Grants
Figure 16.12 Popular Recipient Organizations: Distribution by Number of Grants
Figure 16.13 Popular Recipient Organizations: Distribution by Grant Amount (USD Million)
Figure 16.14 Grants Analysis: Distribution by Region of Recipient Organization
Figure 17.1 Patent Analysis: Distribution by Type of Patent
Figure 17.2 Patent Analysis: Cumulative Distribution by Patent Publication Year, Since 2020
Figure 17.3 Patent Analysis: Distribution by Type of Patent and Publication Year, Since 2020
Figure 17.4 Patent Analysis: Distribution by Patent Application Year, Since Pre-2019
Figure 17.5 Patent Analysis: Patent Jurisdiction
Figure 17.6 Patent Analysis: Distribution by CPC Symbols
Figure 17.8 Leading Industry Players: Distribution by Number of Patents
Figure 17.9 Leading Non-Industry Players: Distribution by Number of Patents
Figure 17.10 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
Figure 17.11 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Figure 17.12 Patent Analysis: Distribution by Patent Age
Figure 17.13 Continuous Manufacturing: Patent Valuation
Figure 20.1 Biologics Continuous Manufacturing Equipment: Distribution by Type of Equipment
Figure 20.2 Biologics Continuous Manufacturing Equipment: Distribution by Type of Manufacturing Process
Figure 20.3 Biologics Continuous Manufacturing Equipment: Distribution by Stage of Bioprocessing
Figure 20.4 Biologics Continuous Manufacturing Equipment: Distribution by Scale of Operation
Figure 20.5 Biologics Continuous Manufacturing Equipment Providers: Distribution by Year of Establishment
Figure 20.6 Biologics Continuous Manufacturing Equipment Providers: Distribution by Company Size
Figure 20.7 Biologics Continuous Manufacturing Equipment Providers: Distribution by Location of Headquarters
Figure 20.8 Most Active Players: Distribution by Number of Biologics Continuous Manufacturing Equipment Offered
Figure 21.1 Continuous Manufacturing: Phase wise Key Strategies for the Adoption of Continuous Manufacturing Processes
Figure 21.2 Process Development and Implementation (Phase I): Distribution by Type of Strategy Adopted
Figure 21.3 Equipment / Technology Development and Installation (Phase II): Distribution by the Type of Strategy Adopted
Figure 21.4 Facility / Plant Development and Establishment (Phase III): Distribution by the Type of Strategy Adopted
Figure 21.5 Product Development and Manufacturing (Phase IV): Distribution by the Type of Strategy Adopted
Figure 22.1 Modular Construction: Applications
Figure 22.2 Steps Involved in Modular Construction
Figure 22.3 Construction Timeline of Modular and Conventional Buildings
Figure 22.4 Modular Construction: Advantages
Figure 22.5 Modular Facility Manufacturers: Distribution by Type of Industry Served
Figure 22.6 Modular Facility Manufacturers: Distribution by Geographical Coverage
Figure 22.7 Modular Facility Manufacturers: Distribution by Type of Modular Construction
Figure 22.8 Modular Cleanroom Providers: Distribution by Year of Establishment
Figure 22.9 Modular Cleanroom Providers: Distribution by Location of Headquarters
Figure 22.10 Modular Cleanroom Providers: Distribution of Headquarters (Country)
Figure 22.11 Modular Cleanroom Providers: Distribution by Type of Modular Cleanroom Offered
Figure 23.1 Global Installed Biologics Continuous Manufacturing Capacity: Distribution by Range of Installed Capacity (in Liters)
Figure 23.2 Global Installed Biologics Continuous Manufacturing Capacity (in Liters): Distribution by Company Size
Figure 23.3 Global Installed Biologics Continuous Manufacturing Capacity: Distribution by Scale of Operation
Figure 23.4 Global Installed Biologics Continuous Manufacturing Capacity: Distribution by Type of Player
Figure 23.5 Global Installed Biologics Continuous Manufacturing Capacity: Distribution by Location of Continuous Manufacturing Facility
Figure 23.6 Biologics Continuous Manufacturing Capacity Installed in North in North America
Figure 23.7 Biologics Continuous Manufacturing Capacity Installed in Europe
Figure 23.8 Biologics Continuous Manufacturing Capacity Installed in Asia-Pacific
Figure 24.1 Global Installed Continuous Small Molecule Manufacturing Capacity (in Kg/Year): Distribution by Range of Installed Capacity
Figure 24.2 Global Installed Continuous Small Molecule Manufacturing Capacity (in Kg/ Year): Distribution by Company Size
Figure 24.3 Global Installed Continuous Small Molecule Manufacturing Capacity (in Kg/ Year): Distribution by Scale of Operation
Figure 24.4 Global Continuous Small Molecule Manufacturing Capacity: Distribution by Type of Player
Figure 24.5 Global Installed Continuous Small Molecule Manufacturing Capacity: Distribution by Location of Continuous Manufacturing Facility
Figure 24.6 Continuous Small Molecule Manufacturing Capacity Installed in North America
Figure 24.7 Continuous Small Molecule Manufacturing Capacity Installed in Europe
Figure 24.8 Continuous Small Molecule Manufacturing Capacity Installed in Asia-Pacific
Figure 25.1 Global Continuous Manufacturing Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 25.2 Global Continuous Manufacturing Market, Forecasted Estimates (Till 2035): Conservative Scenario (USD Million)
Figure 25.3 Global Continuous Manufacturing Market, Forecasted Estimates (Till 2035): Optimistic Scenario (USD Million)
Figure 26.1 Continuous Manufacturing Market: Distribution by Type of Drug Molecule, 2021, 2025 and 2035
Figure 26.2 Continuous Manufacturing Market for Biologics, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 26.3 Biologics Continuous Manufacturing Market for Upstream Bioprocessing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 26.4 Biologics Continuous Manufacturing Market for Downstream Bioprocessing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 26.5 Continuous Manufacturing for Small Molecules Market, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 26.6 Small Molecules Continuous Manufacturing Market for Active Pharmaceutical Ingredients, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 26.7 Small Molecules Continuous Manufacturing Market for Finished Drug Forms, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 27.1 Biologics Continuous Manufacturing Market: Distribution by Scale of Operation, 2021, 2025 and 2035
Figure 27.2 Biologics Continuous Manufacturing Market for Preclinical / Clinical Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 27.3 Biologics Continuous Manufacturing Market for Commercial Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 27.4 Small Molecules Continuous Manufacturing Market: Distribution by Scale of Operation, 2021, 2025 and 2035
Figure 27.5 Small Molecules Continuous Manufacturing Market for Preclinical / Clinical Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 27.6 Small Molecules Continuous Manufacturing Market for Commercial Scale Operations, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 28.1 Biologics Continuous Manufacturing Market: Distribution by Purpose of Manufacturing, 2021, 2025 and 2035
Figure 28.2 Biologics Continuous Manufacturing Market for Contract Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 28.3 Biologics Continuous Manufacturing Market for In-House Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 28.4 Biologics Continuous Manufacturing Market for Both, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 28.5 Small Molecules Continuous Manufacturing Market: Distribution by Purpose of Manufacturing
Figure 28.6 Small Molecules Continuous Manufacturing Market for Contract Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 28.7 Small Molecules Continuous Manufacturing Market for In-House Manufacturing, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 28.8 Small Molecules Continuous Manufacturing Market for Both, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 29.1 Biologics Continuous Manufacturing Market: Distribution by Company Size, 2021, 2025 and 2035
Figure 29.2 Biologics Continuous Manufacturing Market for Small Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 29.3 Biologics Continuous Manufacturing Market for Mid-Sized Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 29.4 Biologics Continuous Manufacturing Market for Large Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 29.5 Small Molecules Continuous Manufacturing Market: Distribution by Company Size, 2021, 2025 and 2035
Figure 29.6 Small Molecules Continuous Manufacturing Market for Small Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 29.7 Small Molecules Continuous Manufacturing Market for Mid-Sized Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 29.8 Small Molecules Continuous Manufacturing Market for Large Companies, Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.1 Biologics Continuous Manufacturing Market: Distribution by Key Geographical Regions, 2021, 2025 and 2035
Figure 30.2 Biologics Continuous Manufacturing Market in North America: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.3 Biologics Continuous Manufacturing Market in the US: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.4 Biologics Continuous Manufacturing Market in Puerto Rico: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.5 Biologics Continuous Manufacturing Market in Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.6 Biologics Continuous Manufacturing Market in Germany: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.7 Biologics Continuous Manufacturing Market in Switzerland: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.8 Biologics Continuous Manufacturing Market in Belgium: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.9 Biologics Continuous Manufacturing Market in Ireland: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.10 Biologics Continuous Manufacturing Market in France: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.11 Biologics Continuous Manufacturing Market in Rest of Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.12 Biologics Continuous Manufacturing Market in Asia-Pacific: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.13 Biologics Continuous Manufacturing Market in China: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.14 Biologics Continuous Manufacturing Market in South Korea: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.15 Biologics Continuous Manufacturing Market in Singapore: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.16 Biologics Continuous Manufacturing Market in Taiwan: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.17 Biologics Continuous Manufacturing Market in India: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.18 Biologics Continuous Manufacturing Market in Japan: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.19 Biologics Continuous Manufacturing Market in Australia: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.20 Biologics Continuous Manufacturing Market: Market Movement Analysis
Figure 30.21 Biologics Continuous Manufacturing Market: Penetration Growth (P-G) Matrix
Figure 30.22 Small Molecules Continuous Manufacturing Market: Distribution by Key Geographical Regions, 2021, 2025 and 2035
Figure 30.23 Small Molecules Continuous Manufacturing Market in North America: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.24 Small Molecules Continuous Manufacturing Market in the US: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.25 Small Molecules Continuous Manufacturing Market in Mexico: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.26 Small Molecules Continuous Manufacturing Market in Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.27 Small Molecules Continuous Manufacturing Market in Germany: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.28 Small Molecules Continuous Manufacturing Market in the UK: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.29 Small Molecules Continuous Manufacturing Market in Italy: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.30 Small Molecules Continuous Manufacturing Market in Switzerland: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.31 Small Molecules Continuous Manufacturing Market in France: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.32 Small Molecules Continuous Manufacturing Market in Belgium: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.33 Small Molecules Continuous Manufacturing Market in Rest of Europe: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.34 Small Molecules Continuous Manufacturing Market in Asia-Pacific: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.35 Small Molecules Continuous Manufacturing Market in China: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.36 Small Molecules Continuous Manufacturing Market in Singapore: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.37 Small Molecules Continuous Manufacturing Market in Japan: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.38 Small Molecules Continuous Manufacturing Market in India: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 30.39 Small Molecules Continuous Manufacturing Market in South Korea: Historical Trends (Since 2021) and Forecasted Estimates (Till 2035) (USD Million)
Figure 34.1 Concluding Remarks: Market Landscape (Biologics Continuous Manufacturing)
Figure 34.2 Concluding Remarks: Market Landscape (Small Molecules Continuous Manufacturing)
Figure 34.3 Concluding Remarks: Partnerships and Collaboration
Figure 34.4 Concluding Remarks: Recent Expansions
Figure 34.5 Concluding Remarks: Grant Analysis
Figure 34.6 Concluding Remarks: Patent Analysis
Figure 34.7 Concluding Remarks: Capacity Analysis
Figure 34.8 Concluding Remarks: Market Forecast and Opportunity Analysis (Biologics Continuous Manufacturing)
Figure 34.9 Concluding Remarks: Market Forecast and Opportunity Analysis (Small Molecules Continuous Manufacturing)

02-2729-4219

+886-2-2729-4219

License/价格

连续生产市场：产业趋势及全球预测（至 2035 年）－依药物分子、生物製程阶段、产品类型、企业规模、生产用途、公司规模及主要地区划分

Continuous Manufacturing Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Drug Molecule, Stage of Bioprocessing, Product Manufactured, Scale of Operation, Purpose of Manufacturing, Company Size, and Key Geographical Regions

连续生产市场

连续生产市场：成长与趋势

连续製造市场：关键洞察

目前，连续生物製药生产商的市场格局高度分散，既有新进入者，也有老牌企业。这些公司大多位于美国。

2. 全球有超过 45 家公司提供采用连续製造技术的生物製剂合约生产服务。其中 80% 的公司生产活性药物成分。

3. 为因应日益增长的生物製剂需求，各公司正在加强其在连续製造技术方面的技术专长，以高效生产高品质产品。

4.约有 50 家製造商声称拥有小分子药物的连续生产技术。其中超过 80% 的公司是大型或超大型企业。

5. 超过 80% 的小分子药物製造商采用连续生产技术，专注于使用流动技术进行原料药合成，从而提高其生产製程的安全性、效率和成本效益。

6. 约 55% 的连续生产合作项目是在过去三年内达成的，其中大部分是生产合约。

7. 约 35% 的公司正在建设新的生产设施，其中约 50% 的公司专注于生物製药和小分子药物的临床和商业规模连续生产。

8. 已向与连续生产相关的研究授予了总计 2500 万美元的资助，其中约 30% 的资助期限最长为三年。

9. 自 2020 年以来，已授予约 80 项与连续生产相关的专利。此外，其中大多数专利的独占期还有 17 年。

10. 目前，全球生物製药连续生产设施的总产能估计约为 225,000 公升。其中约 40% 的产能位于欧洲公司的设施中。

11. 在欧洲，约50%的总装置容量集中在提供临床和商业规模生产的大型製造工厂。

12. 预计2035年，生物製药连续生产市场将以4.9%的复合年增长率成长。目前，上游生物加工占了大部分市场占有率，其次是下游生物加工。

13. 目前，小分子药物占连续生产市场总量的65%以上。预计到2035年，北美将占主导地位，市场占有率超过90%。

连续生产市场：主要区隔市场

连续生产市场的主要参与者

目录

第一部分：报告概述

第一章：引言

第二章：研究方法

第三章：市场动态

第四章：宏观经济指标

第二部分：质性分析

第五章：摘要整理

第六章：引言

第三部分：市场概览

第七章 市场格局：生物製剂连续生产商

第八章：竞争分析：生物製药连续生产商

第九章：市场格局：小分子药物连续生产商

第十章：竞争分析：小分子药物生产者

第四部分：公司简介

第十一章：公司简介：北美连续生产服务供应商

第十二章 公司简介：欧洲连续生产服务供应商

第十三章 公司简介：亚太地区连续生产服务提供者

第五章：市场趋势

第十四章：合作关係合作

第15章：近期扩张

第16章：资助分析

第17章：专利分析

第18章：连续生物製程相关差距

第19章：内部能力与公司努力

第20章：案例研究1：生物製剂连续生产设备

第21章：案例研究2：连续生产实施路线图

第22章：案例研究3：製药/生技产业的模组化设施

第23章：产能分析：连续生物药厂

第24章：产能分析：连续小分子药物生产商

第六部分：市场预测与机会分析

第25章：全球连续生产市场

第26章：连续生产市场（依药物分子划分）

第27章：连续生产市场（依企业规模划分）

第28章：连续生产市场（依製造目标划分）

第29章：连续製造市场（依公司规模划分）

第30章：连续製造市场（依主要地区划分）

第七部分：依地理区域划分的市场机会分析

第31章：市场机会分析：北美

第32章：市场机会分析：欧洲

CONTINUOUS MANUFACTURING MARKET

CONTINUOUS MANUFACTURING MARKET: GROWTH AND TRENDS